Mark Cuban says insurers and PBMs wield undue influence over U.S. drug pricing

Mark Cuban says insurers and PBMs wield undue influence over U.S. drug pricing
Cuban flags PBM insurer concerns

Concerns over the influence of insurance companies and pharmacy benefit managers (PBMs) on the U.S. pharmaceutical supply chain are growing. Mark Cuban, a prominent entrepreneur, commented on social media about how the same firms accused of denying patient claims are also benefiting from strategic relationships related to formulary access. Cuban challenged industry members to address market dynamics where PBMs and insurers wield significant power, particularly regarding pricing and distribution practices. The ongoing debate in the U.S. healthcare sector centers on transparency and accountability, with tensions mounting between manufacturers, distributors, and intermediaries.

Cuban has previously commented on structural challenges in U.S. health care. He described large hospitals as a key obstacle in a recent statement on major hospital systems. Cuban has also made public comparisons of technology platforms, contrasting feedback from Claude AI with that from Johnny Roastbeef in a separate online discussion.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.